Sphingosine 1 Phosphate (S1P) is a key component of the sphingolipid signaling cascade. S1P initiates a proliferative, pro-angiogenic, and anti-apoptotic sequence of events contributing to cancer progression.
Recent research has suggested that S1P is a potent tumorigenic growth factor that is likely released from tumor cells and that S1P may be a novel biomarker for early stage cancer detection. Sphingosine kinase has also been shown to be up-regulated in a variety of cancer types (S1P is produced via the activity of sphingosine kinase phosphorylating sphingosine).

The new Echelon S1P Assay is a sensitive and robust method for the quantification of S1P in a 96-well plate format based on the anti-cancer drug candidate, Sphingomab™.

• A sensitive and robust method for the quantification of S1P in a 96-well plate format
• Competitive ELISA
• Quantitative: 2 µM - 0.06 µM
• Coefficient of variation: less than 12%

Access the S1P ELISA product file


For more information download the poster presented at 2007 Tucson Lysosphingolipid Conference.

Press release: Echelon and Lpath introduce new cancer research assay based on Lpath’s breakthrough anti-cancer drug candidate, Sphingomab™.